Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability.
Natalizumab to fingolimod: Questions answered, unanswered, and unasked.
Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America.
Neuroinflammation and demyelination from the point of nitrosative stress as a new target for neuroprotection.
Neuroprotective effects of a polyphenolic white grape juice extract in a mouse model of experimental autoimmune encephalomyelitis.
iNKT-cells and their ligands: focus on multiple sclerosis.
Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review.
Isolated paroxysmal dysarthria caused by a single demyelinating midbrain lesion.
Comparison of diabetes patients with "demyelinating" diabetic sensorimotor polyneuropathy to those diagnosed with CIDP.
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.
Epigenetic in Multiple Sclerosis: Molecular mechanisms and dietary intervention.
Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions.
Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis.
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.
[Clinical and magnetic resonance imaging features of neuromyelitis optics with positive anti-nuclear antibody serum].
An ex-vivo multiple sclerosis model of inflammatory demyelination using hyperbranched polymer.
Assessing dalfampridine efficacy in the physician's office.
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.
Sarcoidosis with neurological involvement imitating multiple sclerosis: The importance of thoracic imaging.
PML in a patient with lymphocytopenia treated with dimethyl fumarate.
Sex-specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline.
Depressive syndromes in neurological disorders.
Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary.
Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study.
Inflammatory Cytokines and Physical Activity in Multiple Sclerosis.
Pages
« first
‹ previous
…
581
582
583
584
585
586
587
588
589
…
next ›
last »